Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin plus donor lymphocyte infusion for post-allogeneic transplant relapsed Hodgkin lymphoma
ACTRN12619000581167Phase 2Recruiting
- Sponsor
- Melbourne Health
- Start
- Mar 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin and donor lymphocytes in Hodgkin lymphoma (HL), sponsored by Melbourne Health. Primary endpoint: Overall response rate. Started Mar 2019; status: recruiting.
02
Drugs
brentuximab vedotindonor lymphocytes
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on ACTRN12619000581167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000581167.